Auxilium Signs Sobi As Pfizer Replacement In Europe
This article was originally published in The Pink Sheet Daily
The maker of Xiaflex/Xiapex has found a new commercialization partner in the EU after its first partnership fell apart due to disappointing sales of the drug in those territories.
You may also be interested in...
Sobi also gets two oral formulations of Orfadin for the rare genetic disorder HT-1 and is starting over with a new candidate in a collaboration with Affibody.
The manufacturer expected Xiaflex to take off as a non-invasive, more effective alternative to hand surgery, but the market has been slow to convert, prompting Auxilium to shift around its commercial organization.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.